Extended Data Fig. 3: Treatment effects in the semaglutide 0.4 mg group versus the placebo group at weeks 28, 52 and 72 for each of the four SomaSignal NASH tests. | Nature Medicine

Extended Data Fig. 3: Treatment effects in the semaglutide 0.4 mg group versus the placebo group at weeks 28, 52 and 72 for each of the four SomaSignal NASH tests.

From: Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

Extended Data Fig. 3

Mixed model for repeated measurements. Data are presented as estimated treatment ratio and 95% confidence intervals. For each component of MASH, the number of patients at week 28, 52 and 72 was 63, 65 and 67, respectively. MASH, metabolic dysfunction-associated steatohepatitis; OD, once daily.

Source data

Back to article page